Taken together, increased recognition of diabetic enteropathy may allow earlier diagnosis and intervention. This gives rise to hope for the recognition of diabetic enteropathy at an earlier time and specific diagnoses in the future. Finally, more targeted nonpharmacological and pharmacological treatments and interventions can be individually tailored based on pathophysiological findings, in order to improve patient outcomes (Journal of Diabetes Research)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Diabetes and Diet: A Patient and Dietitian’s Perspective
This article has been co-authored by a patient with type 2 diabetes and a specialist dietitian. Here they discuss the patient’s experience and difficulties with controlling weight and strategies that can help a patient in this situation (Diabetes Therapy)
Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
We conclude that using TI appropriately at mealtimes with supplemental dosing improves prandial glucose (TIR and 1–4 h) control without any increase in time in hypoglycemia or weight gain in patients with T1DM on MDI (Diabetes Technology and Therapeutics)
Neuropad for detecting preclinical diabetic peripheral neuropathy
The case for adopting Neuropad to detect preclinical diabetic peripheral neuropathy is not supported by the evidence (NICE)
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Restricting therapy for T1DM to insulin replacement is perhaps an over-simplistic approach, and we focus in this work on reviewing the role of adjuvant therapy in this population (Diabetes Therapy)
Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy
Women with history of HDP are not only at higher risk of cardiometabolic disease during their reproductive years, but HDP is also associated with midlife T2D development above and beyond established risk factors (Cardiovascular Diabetology)
Positive 15-month results with Diamyd® in Type 1 diabetes
When all patients have been followed for 15 months in the diabetes trial DIAGNODE-1, where the diabetes vaccine Diamyd® is given directly into the lymph node, a clearly positive and clinically relevant effect is seen in improving the clinical course and maintaining the endogenous insulin production in newly diagnosed type 1 diabetes (Diamyd Medical)
Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study
The development of T2D in an incident population of PsA is significantly higher than in psoriasis alone or in a general population, whereas the increased risk of cardiovascular disease in PsA and psoriasis is similar (Rheumatology)
Longitudinal relationship between retinal diabetic neurodegeneration and progression of diabetic retinopathy in patients with type 2 diabetes
Progressive loss of mGCIPL is an independent risk factor for progression in early-stage DR. Further assessment of autonomic and peripheral nerve functions can increase sensitivity in predicting aggravation of DR in patients with T2DM (American Journal of Ophthalmology)
Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Older Patients with Type 2 Diabetes: a Real-World Evidence Study
This study’s findings provide evidence of clinically-meaningful reductions in HbA1c, body weight, and SBP in older T2D patients on combined regimens. The dropout and hypoglycemia rate were minimal and treatment was tolerated well (Canadian Journal of Diabetes)
Inpatient hypoglycaemia; should we should we focus on the guidelines, the targets or our tools?
These guidelines suggest using lower limits of glucose targets varying from 4.0 to 6.0 mmol/l [2–4]. Levy et al. propose a lower glucose limit of 5 mmol/l with the catchphrase ‘stop at 5 and keep the inpatient alive’ (Diabetic Medicine)
Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
This article, co-authored by a patient living with type 2 diabetes and a diabetes specialist physician, discusses the patient’s experience of living with type 2 diabetes, including their experience of diagnosis and self-management, education and adoption of SGLT2 inhibitors to treat the disease. The physician discusses the therapeutic challenges of SGLT2 inhibitors and the importance of education (Diabetes Therapy)
Biomarkers in Islet Cell Transplantation for Type 1 Diabetes
Recent advances in identifying accurate beta cell-specific biomarkers such as differentially methylated insulin cell-free DNA and circulating miRNA-375 may help predict clinical outcomes (Current Diabetes Reports)
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings
Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus (Annals of Internal Medicine)
Metformin is the key factor for elevated plasma GDF‐15 levels in type 2 diabetes: a nested, case‐control study
The relatively higher GDF‐15 bioavailability might contribute to explain the protective cardiovascular effects of metformin (Diabetes, Obesity and Metabolism)
Effectiveness of educational intervention based on psychological factors on achieving health outcomes in patients with type 2 diabetes
The results of this study shed light on the importance of the effectiveness of psychological factors on achieving health outcomes in patients with type 2 diabetes (T2D). Moreover, a new combination of diet-related psychological factors in patients with diabetes was introduced in the present study (Diabetology & Metabolic Syndrome)
Optimization of kidney dysfunction prediction in diabetic kidney disease using targeted metabolomics
Targeted metabolomics using blotted samples in filter paper is a simple, low-cost approach to identify outcomes associated with DKD; the inclusion of metabolomics improves predictive capacity of clinical models to identify kidney dysfunction and DKD-related outcomes (Acta Diabetologica)
Immune Mechanisms and Pathways Targeted in Type 1 Diabetes
Herein, we review emerging T1D biomarkers within the context of recent and ongoing T1D immunotherapy trials. We also discuss responder/non-responder analyses in an effort to identify therapeutic mechanisms, define actionable pathways, and guide subject selection, drug dosing, and tailored combination drug therapy for future T1D trials (Current Diabetes Reports)
Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk
This study suggests a paradoxical association of BMI with cardiovascular and mortality risks in different ethnic groups, which may partially be driven by different cardiovascular and glycaemic risk profiles at diagnosis (Acta Diabetologica)
The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices
This study shows that in patients with T2D on insulin therapy, increased urinary ACR is independently associated with an increased risk of major adverse CV events and all-cause mortality (Nephrology Dialysis Transplantation)
- 1
- 2
- 3
- …
- 166
- Next Page »
Glycosmedia is also available as an App: